27 related articles for article (PubMed ID: 12584562)
1. Human Endogenous Retrovirus K Envelope in Spinal Fluid of Amyotrophic Lateral Sclerosis Is Toxic.
Steiner JP; Bachani M; Malik N; DeMarino C; Li W; Sampson K; Lee MH; Kowalak J; Bhaskar M; Doucet-O'Hare T; Garcia-Montojo M; Cowen M; Smith B; Reoma LB; Medina J; Brunel J; Pierquin J; Charvet B; Perron H; Nath A
Ann Neurol; 2022 Oct; 92(4):545-561. PubMed ID: 35801347
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic K-Ras upregulates ITGA6 expression via FOSL1 to induce anoikis resistance and synergizes with αV-Class integrins to promote EMT.
Zhang K; Myllymäki SM; Gao P; Devarajan R; Kytölä V; Nykter M; Wei GH; Manninen A
Oncogene; 2017 Oct; 36(41):5681-5694. PubMed ID: 28604746
[TBL] [Abstract][Full Text] [Related]
3. Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules.
Pradip D; Bouzyk M; Dey N; Leyland-Jones B
Am J Cancer Res; 2013; 3(2):173-95. PubMed ID: 23593540
[TBL] [Abstract][Full Text] [Related]
4. Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study.
dos Santos PB; Zanetti JS; Ribeiro-Silva A; Beltrão EI
Diagn Pathol; 2012 Aug; 7():104. PubMed ID: 22894137
[TBL] [Abstract][Full Text] [Related]
5. Integrins in cancer: biological implications and therapeutic opportunities.
Desgrosellier JS; Cheresh DA
Nat Rev Cancer; 2010 Jan; 10(1):9-22. PubMed ID: 20029421
[TBL] [Abstract][Full Text] [Related]
6. Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus.
Lerdrup M; Bruun S; Grandal MV; Roepstorff K; Kristensen MM; Hommelgaard AM; van Deurs B
Mol Biol Cell; 2007 Sep; 18(9):3656-66. PubMed ID: 17626164
[TBL] [Abstract][Full Text] [Related]
7. Contributions of the alpha6 integrins to breast carcinoma survival and progression.
Chung J; Mercurio AM
Mol Cells; 2004 Apr; 17(2):203-9. PubMed ID: 15179031
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance.
Tan M; Yu D
Adv Exp Med Biol; 2007; 608():119-29. PubMed ID: 17993237
[No Abstract] [Full Text] [Related]
9. Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
Shimizu H; Seiki T; Asada M; Yoshimatsu K; Koyama N
Oncogene; 2003 Feb; 22(6):831-9. PubMed ID: 12584562
[TBL] [Abstract][Full Text] [Related]
10. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
11. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
12. The integrin, alpha6beta1, is necessary for the matrix-dependent activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells.
Carloni V; Mazzocca A; Pantaleo P; Cordella C; Laffi G; Gentilini P
Hepatology; 2001 Jul; 34(1):42-9. PubMed ID: 11431732
[TBL] [Abstract][Full Text] [Related]
13. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
Yoon SO; Shin S; Lipscomb EA
Cancer Res; 2006 Mar; 66(5):2732-9. PubMed ID: 16510594
[TBL] [Abstract][Full Text] [Related]
14. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions.
Spangenberg C; Lausch EU; Trost TM; Prawitt D; May A; Keppler R; Fees SA; Reutzel D; Bell C; Schmitt S; Schiffer IB; Weber A; Brenner W; Hermes M; Sahin U; Türeci O; Koelbl H; Hengstler JG; Zabel BU
Cancer Res; 2006 Apr; 66(7):3715-25. PubMed ID: 16585198
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
